Sanofi
SNYHealthcareNASDAQDrug Manufacturers - General · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Sanofi (SNY) is listed under Drug Manufacturers - General. Valued at $106.91B, SNY is a large-cap name in its sector. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Market Cap
$106.91B
Beta
0.28
P/E (TTM)
19.59
P/E (Fwd)
8.69
EPS (TTM)
$2.28
EPS (Fwd)
$5.14
ROE
6.6%
ROA
4.7%
Cash
$5.54B
Total Debt
$20.02B
Free CF
$16.67B
52W Change
-7.6%
Annual Financials
Cash vs Debt
Sanofi carries $20.02B in total debt against $5.54B in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $16.67B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 6.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $40.56B to $46.72B.
The relatively low beta of 0.28 suggests SNY is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sanofi and its sector.